Drugs.com Clinical Trial ResultsOriginal article
Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
Phase 2positiveLitifilimabPositive
AI Analysis
Summary
Biogen announced positive 52-week Phase 2 data from the AMETHYST study showing litifilimab demonstrates rapid and durable efficacy in cutaneous lupus erythematosus, reinforcing its potential as a first-in-class therapy.
Clinical Trial Data
Phase
Phase 2/3
Primary Endpoint
Met
Outcome Details
52-week Phase 2 data demonstrates rapid and durable efficacy; described as reinforcing potential as first-in-class therapy
Importance:7/10
Sentiment:
0.85
Phase 2 dataCutaneous lupus erythematosusFirst-in-classImmunology
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on October 2, 2026 8:10 PM